Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Short Interest Rises 1,421.2%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 89,977 shares, an increase of 1,421.2% from the September 15th total of 5,915 shares. Approximately 6.1% of the shares of the company are sold short. Based on an average daily volume of 32,888 shares, the short-interest ratio is presently 2.7 days.

Global X Genomics & Biotechnology ETF Stock Performance

NASDAQ GNOM traded up $2.92 during trading on Friday, reaching $68.75. The company’s stock had a trading volume of 24,290 shares, compared to its average volume of 20,312. The firm has a market cap of $101.75 million, a price-to-earnings ratio of -29.38 and a beta of 1.17. Global X Genomics & Biotechnology ETF has a twelve month low of $40.17 and a twelve month high of $74.19. The business’s fifty day moving average price is $64.48 and its 200-day moving average price is $54.66.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Several institutional investors have recently added to or reduced their stakes in GNOM. Polaris Financial Partners purchased a new stake in Global X Genomics & Biotechnology ETF during the 3rd quarter valued at approximately $1,067,000. Bank of America Corp DE grew its stake in shares of Global X Genomics & Biotechnology ETF by 67.8% in the 1st quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock valued at $5,240,000 after purchasing an additional 48,394 shares during the last quarter. Farther Finance Advisors LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF in the third quarter valued at approximately $257,000. Finally, Wealth Management Partners LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF in the first quarter valued at approximately $244,000. Institutional investors and hedge funds own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.